Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PRESS RELEASE NH TherAguix Announces Publication of Groundbreaking Study on AGuIX® Nanoparticles Enhancing Cervical Cancer Treatment Key clinical milestone showcasing the potential of AGuIX®, a...
-
PRESS RELEASE NH TherAguix Announces the completion of Phase I Recruitment for the Pancreas Cohort and the entry into Phase IIin the NANOSMART phase Ib/II trial. Key clinical milestone...
-
PRESS RELEASE Nature's Scientific Reports publishes an article describing the quantification of novel radio-enhancer AGuIX® developed in brain metastases Confirmation, consistently with already...
-
PRESS RELEASE NH TherAguix receives FDA Fast Track designation for AGuIX®, its novel radio-enhancer in the treatment of malignant gliomas, and provides an update on its developments and prospects ...
-
PRESS RELEASE NH TherAguix appoints Jean-Philippe Del as Chief Financial Officer. Paris, January 15th, 2024 – NH TherAguix SA (“NHT”), a Phase II clinical stage biotech company...
-
Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis Recruitment led by...